FDA adds a rare vision-loss warning to Ozempic and other GLP-1 drugs
All GLP-1 drugs, including Ozempic, Wegovy, Zepbound and Mounjaro, must now carry a new warning. It covers NAION, a rare eye condition that can cause permanent vision loss. In FDA data it hit about 6 in 100,000 people on the drugs for a year. On other drugs it was under 4 in 100,000. Novo Nordisk says that is not proof.
Where this came from. 7 outlets reported this. We read them, then wrote the sixty words above.